IRWD

Ironwood Pharmaceuticals Inc

IRWD.US ironwoodpharma.com + Research + Basket
CIK 0001446847
Employees 100
Phone 617 621 7722
Fiscal year end December
IPO Feb 03, 2010
Address 100 Summer Street, Boston, MA, United States, 02110
3.62
+0.01 (+0.28%)
USD · NASDAQ
52-week range
1.61
5.78
Trading at 48% of the 52-week range
Market Cap
596.52M
P/E Ratio
4.69
Forward P/E
12.33
Book Value
-0.98
Div. Yield
N/A
% Institutions
98.93%
% Insiders
3.24%

1 Year

+139.7%

3 Year

-59.5%

10 Year

-66.1%
Description

Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Actions

Add an action for IRWD.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Mr. Thomas A. McCourt CEO & Director 1957
Mr. Ronald Silver Senior VP, Interim CFO, Corporate Controller & Chief Accounting Officer 1982
Dr. Rosario Lobrutto M.B.A., M.S., Ph.D. VP & Global Head of Technical Operations NA
Mr. John Minardo Senior VP, Chief Legal Officer & Secretary 1976
Mr. Jeff Ruberti Chief Strategy Officer NA
Dr. Jeffrey Silber M.D. Chief Medical Officer, Head of Research & Drug Development NA

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Mar 17, 2026 Alexander J Denner N/A Sale 6.73M $3.05 $20.53M SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
BlackRock Inc 17.79M Jun 30, 2026 10.77% $0.00 33.12%
Armistice Capital, LLC 13.93M Jun 30, 2026 8.43% $0.72 -7.29%
Sarissa Capital Management LP 9.19M Jun 30, 2026 5.56% $21.75 0.00%
State Street Corp 8.81M Jun 30, 2026 5.33% $0.00 18.14%
Bank of America Corp 8.68M Jun 30, 2026 5.26% $0.00 0.01%
Renaissance Technologies Corp 7.99M Jun 30, 2026 4.84% $0.05 -0.84%
Vanguard Capital Management, LLC 6.61M Jun 30, 2026 4.00% $0.00 8.38%
AQR Capital Management LLC 6.47M Jun 30, 2026 3.91% $0.01 -14.19%
Acadian Asset Management LLC 5.85M Jun 30, 2026 3.54% $0.03 -11.01%
Vanguard Portfolio Management, LLC 5.51M Jun 30, 2026 3.34% $0.00 -17.49%
Geode Capital Management, LLC 4.83M Jun 30, 2026 2.92% $0.00 6.34%
Two Sigma Investments LLC 4.56M Jun 30, 2026 2.76% $0.01 -22.10%
Marshall Wace Asset Management Ltd 4.29M Jun 30, 2026 2.60% $0.01 -5.19%
Jacobs Levy Equity Management, Inc. 4.07M Jun 30, 2026 2.46% $0.06 11.93%
The Goldman Sachs Group Inc 3.31M Jun 30, 2026 2.01% $0.00 23.16%
Charles Schwab Investment Management Inc 3.30M Jun 30, 2026 2.00% $0.00 -30.30%
Federated Hermes Inc 3.23M Jun 30, 2026 1.96% $0.02 -3.51%
Arrowstreet Capital Limited Partnership 3.02M Jun 30, 2026 1.83% $0.01 -11.19%
Dimensional Fund Advisors, Inc. 2.52M Jun 30, 2026 1.53% $0.00 21.17%
Mackenzie Investments 2.37M Jun 30, 2026 1.43% $0.01 322.74%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard MStar Total Stk Mkt Idx Invest 4.78M 2.89% ▲ 0.00% Sep 30, 2026
2 iShares Russell 2000 ETF 4.25M 2.57% ▼ 1.14% Sep 30, 2026
3 State Street® SPDR® S&P® Biotech ETF 3.34M 2.02% ▼ 1.88% Sep 30, 2026
4 Fidelity Small Cap Index 1.79M 1.08% ▲ 0.90% Jul 31, 2026
5 Vanguard Strategic Equity Inv 1.75M 1.06% ▼ 16.68% Jun 30, 2026
6 iShares Russell 2000 Growth ETF 1.46M 0.88% ▼ 0.13% Sep 30, 2026
7 Vanguard Explorer Inv 1.40M 0.85% ▼ 13.99% Jun 30, 2026
8 Pacer US Small Cap Cash Cows 100 ETF 1.34M 0.81% ▲ 0.23% Sep 30, 2026
9 Federated Hermes MDT Small Cap Core IS 1.29M 0.78% ▲ 0.00% Jun 30, 2026
10 iShares Biotechnology ETF 1.26M 0.76% ▼ 0.75% Sep 30, 2026

Financial Highlights

▼
Market Cap: $596.52M
EBITDA: $238.10M
P/E Ratio: $4.69
PEG Ratio: $-0.26
Book Value: $-0.98
Earnings/Share: $0.77
Profit Margin: 33.36%
Operating Margin: 70.16%
ROA (TTM): 47.02%
ROE (TTM): -574.72%
Revenue (TTM): $389.32M
Revenue/Share (TTM): $2.39
Earnings Growth (YOY): 125.70%
Revenue Growth (YOY): 32.60%

Valuation Metrics

Enterprise Value: $897.73M
Trailing P/E: 4.69
Forward P/E: 12.33

Shares Statistics

Shares Outstanding: 165.24M
Shares Float: 136.76M
% Insiders: 3.24%
% Institutions: 98.93%
Shares Short: 15.89M
Shares Short (Prior Month): 15.57M
Short Ratio: 7.16
Short % Float: 10.50%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$296.15M
Cost of Goods Sold
adjust
$-1.88M
Gross Profit
subtotal
$296.15M
SG&A
adjust
$-82.26M
R&D
adjust
$-95.14M
Operating Income
subtotal
$118.76M
Other / Non-Operating Items
adjust
$-94.74M
Net Income
subtotal
$24.02M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about IRWD.US!